RA shortens life expectancy, even with advances in treatment—and more so for women than for men, according to new research by Chiu et al.
Non-Invasive Vagus Nerve Stimulation Tolerated, Effective for Rheumatoid Arthritis
(Reuters Health)—Non-invasive vagus nerve stimulation is safe and effective as an intervention for rheumatoid arthritis (RA), a small proof-of-concept study suggests. The study enrolled 35 patients with active RA and an inadequate response to therapy with disease-modifying anti-rheumatic drugs (DMARDs). All DMARDS were discontinued four weeks prior to the trial. For the study, all participants…
Micromotors Promising for Rheumatoid Arthritis Therapy
NEW YORK (Reuters Health)—Magnesium-based micromotors showed promise as a delivery system for hydrogen therapy to inflamed joints in an experimental model of rheumatoid arthritis, researchers say. Hydrogen gas has been shown to neutralize overproduction of reactive oxygen species (ROS), which can degrade cartilage and bone and activate inflammatory cytokines, according to Dr. Yingfeng Tu of…
Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks
In Canada, a subcutaneous formulation of CT-P13, which is biosimilar to infliximab, was approved to treat rheumatoid arthritis.
Study Explores Palindromic Rheumatism to Predict RA Development
Research from Ellingwood et al. examines how often patients diagnosed with early RA experience episodic joint inflammation and describes characteristics that may result in RA development.
Modern Treatment Tied to Low Disease Activity in Pregnant RA Patients
(Reuters Health)—Many pregnant women with rheumatoid arthritis (RA) may achieve low disease activity in the third trimester with a modern treatment regimen that includes anti-tumor necrosis factor (TNF) medications, a recent study suggests. Researchers examined data on 309 patients with RA who were pregnant or trying to conceive and who were treated with modern treat-to-target…
Research Outlines Benefits of bDMARDs to Treat Early RA
Sapart et al. suggest a combination of methotrexate and biologic disease-modifying anti-rheumatic drugs as induction therapy for patients with early RA may lead to long-term remission.
A High HAQ at Baseline in Early RA Is a Bad Sign
In this study, Fatima et al. analyzed how well the Health Assessment Questionnaire (HAQ) disability index predicts future all-cause mortality in patients with early RA (i.e., with a symptom duration of less than one year). A total of 1,724 patients with early RA were included. The researchers found that a higher HAQ score and Disease Activity Score at one year were significantly associated with all-cause mortality.
A Closer Look at Antibodies in RA: How Anti-Citrullinated Protein Antibodies, Anti-Modified Protein Autoantibodies & Rheumatoid Factor Activity Overlap
Recent evidence on how anti-citrullinated protein antibodies, anti-modified protein autoantibodies and rheumatoid factor activity overlap in RA demonstrate new ideas for diagnostics and pathophysiology.
Long-Term Safety of Baricitinib for RA
Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 30
- Next Page »